Vasomune Therapeutics Completes Enrollment of Phase 2a Study of Pegevongitide (AV-001) in Patients Hospitalized with Pneumonia/ARDS

Enrollment milestone advances the FDA Fast Track-designated program toward data review and analysis TORONTO — Vasomune Therapeutics Inc. (“Vasomune”), a clinical-stage biopharmaceutical company developing medicines that target endotheliopathy and vascular leak, today announced the completion of patient enrollment in AV001-004 (NCT05123755), its randomized, double-blind, placebo-controlled Phase 2a clinical study evaluating Pegevongitide (AV-001) in patients hospitalized […]